Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 4;182(1):180–189. doi: 10.1111/bjd.17918

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Effect of antidrug antibodies (ADAs) on tildrakizumab (MK‐3222) concentrations for patients treated with 100 mg or 200 mg continuously for 52–64 weeks. (a) Mean concentration–time profiles for patients treated with 100 mg. (b) Individual concentration–time profiles for patients treated with 100 mg. (c) Mean concentration–time profiles for patients treated with 200 mg. (d) Individual concentration–time profiles for patients treated with 200 mg. For (a) and (c), dosing is represented by a solid triangle along the x‐axis. The numbers on the treatment‐emergent‐positive, neutralizing antibody (NAb)‐positive profile represent the number of patients contributing to that time point. For (b) and (d), grey lines represent the concentration–time profile in ADA‐negative patients. Red filled circles represent individual samples that tested positive for ADAs. Continuous treatment with tildrakizumab means that patients treated with placebo or etanercept and then tildrakizumab were not included in the analysis.